CME: Strategies for Improving Outcomes in Patients with Parkinson’s Disease

Strategies for Improving Outcomes in Patients with Parkinson’s Disease

Strategies for Improving Outcomes in Patients with Parkinson’s Disease
RestartResume
Examine advances in pharmacologic and nonpharmacologic interventions with the potential to improve patient outcomes in Parkinson's Disease.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Parkinson’s disease (PD) affects roughly one million Americans and more than 10 million people worldwide. It is a progressive neurologic disorder characterized by motor and nonmotor symptoms. Key motor symptoms include resting tremor, bradykinesia, rigidity, and postural instability. Nonmotor symptoms include psychosis, depression, anxiety, impulse control disorders, cognitive impairment, and sleep disturbances. Significant progress has been made in the management of motor and nonmotor symptoms experienced by patients with PD. This activity will examine advances in pharmacologic and nonpharmacologic interventions that are improving patient outcomes for this incurable condition. 

     

  • Disclosure of Conflicts of Interest

    The Albert Einstein College of Medicine also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States. 

    Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities. 

    FACULTY DISCLOSURES 

    Andrew Wilner, MD
    No conflicts of interest to disclose.

    Michael S. Okun, MD
    No conflicts of interest to disclose.

    Daniel E. Kremens, MD, JD
    Research: Acorda, Enterin, Revance
    Speakers Bureau: Acadia, Adamas, Impax, Teva Pharmaceuticals, UCB, US WorldMeds, Lundbeck 
    Consultant: AbbVie, Allergan, GE Healthcare, Kyowa, Merz, Neurocrine, St. Jude Medical, Sunovion

    David M. Kaufman, MD
    No conflicts of interest to disclose.

    The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests relative to this CME activity. 

    Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose. 
    Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education, has no conflicts of interest to disclose.

    Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, and MCM Education. 

    The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, Acorda, Biogen, Lundbeck, US WorldMeds, or Medtronic. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

  • Target Audience

    Neurologists, movement disorder specialists, NPs, PAs, and nurses involved in the care of patients with Parkinson’s disease

  • Learning Objectives

    Upon completion of this educational activity, participants should be able to:

    1. Review the efficacy and safety of current and emerging therapies for managing the motor symptoms of PD.
    2. Review the efficacy and safety of current and emerging therapies for managing the nonmotor symptoms of PD.
    3. Incorporate currently-approved pharmacologic and nonpharmacologic therapies for the management of PD into individualized treatment plans for patients with PD. 
  • Commercial Support

    This activity is supported by educational grants from Acorda, Biogen, Lundbeck, US WorldMeds, and Medtronic.

  • Accreditation and Credit Designation Statements

    ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Albert Einstein College of Medicine, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. 

    ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CCME Reviewer
    David M. Kaufman, MD
    Professor of Neurology and Psychiatry and Behavioral Sciences
    Albert Einstein College of Medicine
    Montefiore Medical Center
    Bronx, NY

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Global Neurology Academy newsletters.
Comprehensive Neurology Education.

Better education for a better you.

* Required
Optional
Register

Join the Global Neurology Academy of learners.
Registration is free and easy.

Register Now